Use of Melzi Sharps Finder demonstrated to reduce time to locate lost sharps in surgical robotic lab setting
Testing results with the Melzi Sharps Finder show detection of 13mm, 17mm and 26mm needles with a 95% reliability rate
RENO, NV / ACCESSWIRE / October 11, 2022 / Melzi Surgical ("Melzi" or the "Company"), a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses, today highlighted results demonstrating accelerated time in locating lost surgical sharps using the Melzi Sharps Finder.
Over 390,000 sharp objects are lost during surgery each year in the United States.1 The Melzi Sharps Finder is a sterile, single-use sharps detection device and can be used in robotic, laparoscopic and open procedures. When a sharp is lost or miscount is identified, surgeons can activate the Sharps Finder to assist with the search in the surgical area. The use of the Melzi Sharps Finder is intended for preventing retained surgical sharps, reducing search time and resources during lost sharps events and minimizing risks to patients, hospitals and staff.
"These results represent the potential for the Melzi Sharps Finder to locate lost surgical objects in an operating room ("OR") setting. Current protocol for locating a lost sharp object in an OR setting includes identifying a needle is lost, halting surgery, methodical searching for the lost sharp, calling for an X-ray, which can take up to fifteen minutes and retrieval if the X-ray proves the needle is in the patient. With the Melzi Sharps Finder, surgeons are able to use the device to try and locate the lost sharp immediately before the X-ray arrives. If the Sharps Finder locates the lost sharp before the X-ray arrives, the surgical team can then cancel the X-ray order and proceed with surgery, saving valuable time and money," commented Dr. Samuel Weprin, Co-Founder and Product Innovation at Melzi Surgical.
In a surgical robotic lab setting, 3 attending Urogynecological surgeons had the opportunity to identify lost needles using the Melzi Sharps Finder. For the study, the surgeons used a 5.0 suture (13mm needle) and tied the suture to the surgical clamp to ensure no danger was posed to the patient. The simulated lost needle was intentionally hidden behind vaginal wall tissue, as to not make it visible on the laparoscope. The surgeon then inserted the Melzi Sharps Finder through the assistant port and within a minute, the device signaled detection of the lost sharp, guiding the surgical team to retrieve it. Overall, results from this study found that the time to locate (TTL) the lost surgical objects using the Melzi Sharps Finder was less than a few minutes on average, as opposed to a maximum of 40 minutes using current protocol.
"The Melzi Sharps Finder has demonstrated its potential as a real game-changer for any surgical staff in an OR setting," commented Jay Shah, MD, Urology Oncologist, Vice Chief of Staff at Stanford Health Care. "It is easy to use, ergonomic and has proven to save a noteworthy length of time for patients and physicians when lost sharp events take place. Based on the results seen to date, I believe the Melzi Sharps Finder has the potential to be the solution for locating needles and objects lost during surgery - which remains a large and growing problem."
"Lost sharp events across a variety of surgical procedures do happen and perhaps more frequently than commonly thought," commented Daniel D. Eun, MD, Chief, Robotic Surgery at Temple University Hospital, "This adjunct technology offers the ability to accelerate the time it takes to locate a lost sharp during surgery which is crucial to patient safety and OR efficiency. Having a tool such as the Melzi Sharps Finder, which minimizes the chance of prolonged surgery, extended hospital stay, retained surgical item incident and re-operation, can be incredibly valuable."
Melzi is currently leveraging a network of surgical leader champions in key markets and a regional sales distributor network of contractors to establish early adoption. The Company is working towards its planned aggressive national rollout and expansion of distributor network in order to grow awareness and adoption and ultimately drive sales in the United States. In an effort to propel Melzi to its next stage of growth, the Company is actively participating in both surgical and operating room staff conferences and events.
Melzi is a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses. The Company's lead product, the Melzi Sharps Finder, is a U.S. FDA registered device designed to locate instruments, needles, broken pieces and fragments, or sharp objects ("sharps") that have been lost inside a patient during surgery. The Melzi Sharps Finder is an easy-to-use hand tool capable of working in a 5mm trocar for laparoscopic and robotic surgeries and can also be used in open surgery. In a lab study, testing results with the Melzi Sharps Finder show detection of 13mm, 17mm, and 26mm needles with a 95% reliability rate.
The use of an adjunct technology, like the Melzi Sharps Finder, can bring patient safety, time, financial, and risk benefits. The Melzi Sharps Finder is currently indicated for use in gastroenterology and urology surgeries.
For more information about the Company, please visit melzisurgical.com
Investor Contact: Jenene Thomas, JTC Team T: (US): +1 (833) 475-8247 E: melzi@jtcir.com
Business Development Contact: Allen McClinton, Melzi Surgical T: 650-272-8987 E: allen@melzicorp.com
1 North American Lost Sharp Events: 390,000. Retained Surgical Items: A Changing Landscape. Journal of Patient Safety, 2020, Weprin, et al.
View source version on accesswire.com: https://www.accesswire.com/719795/Melzi-Surgical-Technology-the-Melzi-Sharps-Finder-Demonstrates-Accelerated-Time-To-Locate-Lost-Surgical-Needles
Brazilian Butt Lift surgery has taken on a life of its own in the last few years.
Discover more about the medical center in Tijuana where you can receive a treatment with this approach
For the lead doctor, it was an opportunity not only to heal a patient, but to map real-time brain activity during "high cognitive function."
3M Health Care's Medical Solutions Division today announced its 3M™ V.A.C.® Therapy negative pressure wound therapy (NPWT) has surpassed a clinical evidence milestone of 2,000 published, peer-reviewed medical journal studies. V.A.C. Therapy is the first and only NPWT solution to garner this number of published studies about its therapy. It is backed by more clinical data than any other brand, accounting for more than 75% of published NPWT clinical evidence.
The hot inflation report means higher rates in the U.S., driving the dollar up against the yen as Japan remains on hold.
Returns largely determined by time period, fund characteristics.
Reporting year-end results, the group's CEO detailed major moves aimed at giving local operations more decision-making power.
Taiwan Semiconductor, the world's largest contract chipmaker, beat targets for the third quarter and guided higher for the current period.
On the international dimension of the European Union circular economy policy and legal framework
Future Fund Active ETF co-founder Gary Black recommends to Tesla's board how it should spend some of the electric-vehicle company's cash.
MSC Industrial (MSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bitcoin (BTC) tumbled nearly 3% in the minutes after the latest U.S. Consumer Price Index (CPI) report showed inflation rose to a 40-year high in September. "The Hash" panel discusses the inflation numbers and what they mean for the crypto markets.
Shares of Albertsons Cos. Inc. were up more than 11% in Thursday morning trading after Bloomberg News reported that Kroger Co.
Hub stock shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 85.
Delta Air Lines Inc on Thursday forecast stronger-than-expected profit in the fourth quarter as the carrier sees travel demand remaining robust despite growing risks of an economic recession, sending its shares higher. The Atlanta-based carrier expects an adjusted profit of $1.00-$1.25 per share in the quarter through December on a possible 9% jump in revenue from the same period in 2019. U.S. carriers are enjoying the strongest consumer demand in three years.
WILMINGTON, Del. (Reuters) -Elon Musk is being investigated by federal authorities over his conduct in his $44 billion takeover deal for Twitter Inc, the social media company said in a court filing released on Thursday. While the filing said he was under investigations, it did not say what the exact focus of the probes was and which federal authorities are conducting them. Twitter, which sued Musk in July to force him to close the deal, said attorneys for the Tesla Inc CEO had claimed "investigative privilege" when refusing to hand over documents it had sought.
He’ll be around next season, but beyond that is uncertain.
European Central Bank staff see the need for fewer rate hikes than markets now estimate to tame inflation, according to a new internal model that could serve as a key input in future deliberations, four sources close to the discussion said. This is well below markets' estimate for the ECB's deposit rate to peak just over 3%, suggesting that ECB staff consider inflationary pressures more modest than investors and even some central bankers. An ECB spokesman declined to comment.
The non-COVID base business is expected to have gained from Quest Diagnostics' (DGX) efforts to expand value-based contracts with payers.
MarketWatch spoke with former Bridgewater Associates executive Bob Elliott about his new exchange-traded fund tracking hedge-fund returns. Also, Francis Oh of Qraft Technologies weighed in on one of the firm's artificial-intelligence-driven ETFs.